EU faces AstraZeneca’s COVID-19 vaccine shortage amid manufacturing concerns

Follow us on Google News:
 EU faces AstraZeneca’s COVID-19 vaccine shortage amid manufacturing concerns

Source: OrelPhoto, Shutterstock

Summary

  • EU is confronting a shortage of AstraZeneca’s vaccine in its COVID-19 vaccination program.
  • AstraZeneca has raised some manufacturing and export concerns that could decrease vaccine deliveries.
  • Some European countries, including Denmark, Iceland, and Norway, have temporarily stopped the vaccination with AstraZeneca’s jab.

The European Union (EU) is facing a further shortage in its COVID-19 inoculation program after pharmaceutical behemoth AstraZeneca Plc (LON:AZN) raised some manufacturing concerns. British-Swedish drug maker stated that the Company is experiencing lower-than-anticipated output from the production process. The Company also highlighted some export restrictions would decrease the planned vaccine deliveries.

The Anglo-Swedish pharmaceutical Company is already surrounded by controversies, with several EU nations suspending the vaccine rollout amid some blood clot fears. However, the World Health Organization (WHO) stated that there was no reason to terminate the vaccine’s usage.

Source: © Mikemareen| Megapixl.com

Rising production challenges and export restrictions

AstraZeneca highlighted challenges related to manufacturing and export for the shortage of vaccine delivery across the European Union. This is a significant obstacle in efforts to fight the COVID-19 pandemic.

Source: © Andreyyalansky19 | Megapixl.com

Previously, the Company had advised that it was confronting shortfalls from its European supply chain owing to the lower than anticipated production and was expected to compensate in part by obtaining COVID-19 jab from its global network.

Several media reports mention that in a statement, AstraZeneca stated that export restrictions would cut the deliveries during the first quarter. This export restriction is expected to impact deliveries in the second quarter.

DID YOU KNOW: Italy to become the first EU nation to manufacture Russia’s Sputnik V vaccine

AstraZeneca commenced vaccine delivery to the EU in February 2021, and the Company intends to deliver almost 100 million doses in the 1H 2021. Of this, 30 million are expected to be delivered in the first quarter. The British drug developer had initially decided to supply three times as many shots in the first quarter and 180 million in the second quarter.

Blood clot fears with AstraZeneca’s COVID-19 vaccine

Some European nations, including Denmark, Iceland and Norway, have stopped the administration of AstraZeneca’s vaccine amid the concerns of blood coagulation. Meanwhile, India is planning to carry out a detailed review process of its post-vaccination side effects during the upcoming week.

Besides, Thailand also delayed the planned launch of Oxford-AstraZeneca’s vaccine just before the prime minister received the first shot.

However, the WHO’s vaccines advisory committee has emphasised that there is no causal link between AstraZeneca’s jab and blood clotting after investigating the safety data.

ALSO READ: Did you miss these updates on Oxford University-AstraZeneca’s COVID-19 Vaccine?

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK